Navigation Links
Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure

SAN MATEO, Calif., Jan. 8 /PRNewswire/ -- Corthera Inc. today announced the initiation of patient enrollment in a Phase II clinical trial of Relaxin, a naturally occurring peptide hormone that is being developed for acute heart failure and other acute care illnesses.

The trial will investigate the efficacy and safety of Relaxin in patients with acute heart failure. Approximately 330 patients will be recruited from more than 50 investigational centers worldwide. The primary outcome measure is the improvement of clinical signs and symptoms of acute heart failure, with additional secondary outcome measures, including improvement in renal function.

"With the current lack of safe and effective therapies for acute heart failure, we are very pleased to advance the development of Relaxin for the benefit of these patients," said Stan E. Abel, president and chief executive officer of Corthera. "The clinical and preclinical results to date are very encouraging, demonstrating Relaxin's beneficial hemodynamic properties."

According to the American Heart Association, heart failure is a costly cardiac and renal syndrome affecting more than 550,000 new patients per year, with projected direct and indirect costs at $33.2 billion in 2007. Acute heart failure is characterized by fluid overload (congestion), especially in the lungs, that causes shortness of breath and other complications. The current standard of care includes diuretics and vasodilators. Diuretics, which promote fluid excretion, are associated with renal complications. Vasodilators tested to date have been linked to hypotension, renal impairment and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a targeted vasodilator with demonstrated systemic and renal hemodynamic effects. Elevated levels of Relaxin are thought to modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured Relaxin has been shown to have these effects in multiple human studies of men and non- pregnant women. Data from a pilot study in patients with heart failure support the expectation that these effects can be beneficial in relieving the signs and symptoms of heart failure.

About Corthera

Corthera Inc. is a biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, Relaxin, is currently being evaluated in clinical trials for acute heart failure and preeclampsia. Corthera has worldwide rights to develop and commercialize Relaxin.

Contact: Timothy Engel or David Schull

Russo Partners


SOURCE Corthera Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
3. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
7. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
8. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
9. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
Post Your Comments:
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... The hospitals ... to several aspects of orthopedic care. They have received recognition for excellence from ... orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based on ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for ... with some of the staff members at their recovery center. The videos highlight some ... as some of the things that make their recovery program so unique. , “Making ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... award at Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, ... Chiropractor and University President Carl S. Cleveland III on October 16. , “Katie ...
Breaking Medicine News(10 mins):